Portal de Periódicos da CAPES

Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer

2015; Elsevier BV; Volume: 27; Issue: 2 Linguagem: Inglês

10.1093/annonc/mdv560

1569-8041

T. Donnem, Thomas K. Kilvaer, Sigve Andersen, Elin Richardsen, Erna‐Elise Paulsen, Sigurd M. Hald, Samer Al‐Saad, Odd Terje Brustugun, Åslaug Helland, Marius Lund‐Iversen, Steinar Solberg, Bjørn Henning Grønberg, Sissel Gyrid Freim Wahl, Lars Helgeland, Øystein Fløtten, Mette Pøhl, Khalid Al‐Shibli, Torkjel M. Sandanger, Francesco Pezzella, L. T. Busund, Roy M. Bremnes,

Inflammatory Biomarkers in Disease Prognosis

ABSTRACT Immunoscore is a prognostic tool defined to quantify in situ immune cell infiltrates and appears highly promising as a supplement to the tumor–node–metastasis (TNM) classification of various tumors. In colorectal cancer, an international task force has initiated prospective multicenter studies aiming to implement TNM-Immunoscore (TNM-I) in a routine clinical setting. In breast cancer, recommendations for the evaluation of tumor-infiltrating lymphocytes (TILs) have been proposed by an international working group. Regardless of promising results, there are potential obstacles related to implementing TNM-I into the clinic. Diverse methods may be needed for different malignancies and even within each cancer entity. Nevertheless, a uniform approach across malignancies would be advantageous. In nonsmall-cell lung cancer (NSCLC), there are several previous reports indicating an apparent prognostic importance of TILs, but studies on TILs in a TNM-I setting are sparse and no general recommendations are made. However, recently published data is promising, evoking a realistic hope of a clinical useful NSCLC TNM-I. This review will focus on the TNM-I potential in NSCLC and propose strategies for clinical implementation of a TNM-I in resected NSCLC.